Dr. Dreicer on Abiraterone and Enzalutamide in Prostate Cancer

Robert Dreicer, MD
Published: Thursday, Mar 23, 2017



Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses abiraterone acetate (Zytiga) and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

The decision whether to treat a patient with either abiraterone or enzalutamide as initial treatment usually depends on the patient profile. Abiraterone requires low-dose prednisone, while enzalutamide has potential CNS toxicities, which allows clinicians to choose the most appropriate treatment based on each individual patient.
 


Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses abiraterone acetate (Zytiga) and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

The decision whether to treat a patient with either abiraterone or enzalutamide as initial treatment usually depends on the patient profile. Abiraterone requires low-dose prednisone, while enzalutamide has potential CNS toxicities, which allows clinicians to choose the most appropriate treatment based on each individual patient.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x